Trevi Therapeutics Goes Up Against Cara In Itch

Trevi Therapeutics has announced positive Phase II/III results for its lead product nalbuphine ER tablets in treating uremic pruritus.

Uremic pruritus is a persistent and debilitating itch that occurs in kidney disease patients on dialysis